Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56. [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 438. 2016 Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Carcinoma, Renal Cell; Humans; Kidney Neoplasms Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32017000114 Date abstract record published 17/01/2017 |